Shinpoong Publishes Corporate Governance Report: Self-Share Cancellation of 11B KRW and Profit Turnaround, but Multiple Governance Deficiencies and Lack of Shareholder Return Policy
Shinpoong Pharmaceutical disclosed its 2026 Corporate Governance Report on May 28, 2026, announcing the completion of a self-share cancellation of approximately 11 billion KRW (566,468 common shares and 208,770 preferred shares) to enhance shareholder value.
In 2025, the company turned to profit with consolidated revenue of 234.7 billion KRW and operating profit of 14.3 billion KRW, but paid no dividends and failed to establish a mid-to-long-term shareholder return policy.
The company failed to comply with several core governance indicators (e.g., 4-week advance notice of shareholder meeting, dividend predictability, CEO succession policy, risk management policy, gender diversity), highlighting the need for governance improvement.
During the reporting period, the company was designated as a 'unfaithful disclosure entity' and fined 8 million KRW for delayed disclosure of embezzlement/breach of trust, and subsequently strengthened internal controls.
The company issued 11.5 billion KRW in exchangeable bonds (based on treasury shares, exchange price 16,193 KRW) to fund production facility investments, minimizing dilution for existing shareholders.
[AI Comprehensive Analysis]Shinpoong attempted to enhance shareholder value through profit turnaround and stock cancellation, but risks from lack of dividends and multiple governance non-compliance remain. Future stock price outlook hinges on the establishment of shareholder return policies and improvement in governance practices.